NY-TERRAFORMATION
3.11.2022 08:22:41 CET | Business Wire | Press release
Terraformation, a global reforestation company, has launched the Seed to Carbon Forest Accelerator, the world’s first biodiversity-focused, carbon-funded forest accelerator program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005421/en/
Photo: The Kilimanjaro Project (Photo: Business Wire)
In the next decade, the world will need thousands of new reforestation teams to capture carbon at scale and limit the impacts of climate change. The new forest accelerator will help meet this need by providing forestry teams with the tools to launch restoration projects and succeed at scale. These include early-stage financing, training in resilient native ecosystem restoration, and tools to increase project transparency in critical early stages.
This wraparound platform to launch emerging forestry teams is unique in the industry and brings much-needed support to expand the supply of forest carbon.
The carbon buyers and companies who provide early financing to accelerator cohorts lock in access to the premium-quality carbon credits the projects generate. By providing this financing, buyers secure access to a portfolio of verified carbon credits from geographically diverse projects selected by the company’s carbon science team. Terraformation is looking to connect with finance partners to launch a new accelerator cohort early next year.
The accelerator program is a direct response to the largest bottlenecks to mass-scale restoration: in a recent Terraformation survey of 230 forestry organizations around the globe, 95% of respondents said funding was their biggest concern.[1]
The accelerator builds on Terraformation’s successful pilot restoration projects. Since the company began its global programs in 2020, it has successfully launched 16 restoration projects across 11 countries and created more than 400 new sustainable jobs.
Yishan Wong, founder and CEO of Terraformation, said: “The planet needs to rapidly scale reforestation efforts to address the climate crisis. And more investors than ever are looking for opportunities in carbon capture. But there hasn’t been a clear vehicle providing those investors access to high-quality carbon credits. At the same time, communities around the world are launching vital restoration efforts, but lack the funding, training and technology they need to scale.
“Our accelerator will rapidly expand the number of high-quality forest restoration projects and increase the planet’s capacity for carbon capture.”
María José Iturralde, co-founder of Humans for Abundance, a Terraformation restoration partner, said: “Funding can turn land management around by supporting new sustainable business models that replace deforestation for profit. Startup capital creates opportunities for training, education and infrastructure that allows communities to sustainably restore ecosystems and commercialize their new products in a new way.”
Apply to the accelerator
Applying to and participating in the Seed to Carbon Forest Accelerator is free and open to all forestry teams that prioritize biodiversity and benefits to local communities. Interested organizations and forestry teams are invited to apply to the accelerator beforeNovember 27, 2022. Read more and apply here.
Selected teams will receive a feasibility study to assess carbon project viability on their land, as well as access to expert training in seed collection and banking, biodiverse forest restoration, sustainable business models, marketing and finance. Teams will also receive access to carbon buyers, as well as to new, state-of-the-art project tracking software to streamline monitoring, reporting and verification of project progress, and more. Terraformation will encourage forestry teams to promote women’s leadership, offer community education and create sustainable, local economic impact.
Forestry teams selected to participate in the first cohort will be announced in early 2023.
Fund new forest carbon projects
Carbon buyers and companies interested in funding accelerator forest projects and accessing premium-quality, biodiverse, verified carbon credits can learn more here.
*ENDS*
NOTE TO EDITORS:
About Terraformation
Terraformation is dedicated to restoring the world’s forests to stabilize our climate, revive ecosystems, and build thriving communities.
The company hosts a forest carbon accelerator, supporting early-stage forestry teams to launch, build, and scale biodiverse reforestation projects. In addition to producing high-quality, verified carbon credits, these projects generate complementary sustainable revenue streams to support local economies.
Terraformation’s current partner network spans five continents and includes diverse landowners and organizations. It was founded in 2019 by Yishan Wong, former CEO of Reddit.
Footnotes
[1] Terraformation research conducted in summer 2022 with a survey of 230 respondents from 63 countries. Interviews were also completed with 70 respondents from 29 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom